Malignant Pleural Effusion: Diagnosis and Management | MDster You are offline Back online! [ ](/) Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) Menu Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) [ Login ](https://mdster.com/auth/login) 1. [ Home ](https://mdster.com) 2. [ Blog ](https://mdster.com/blog) 3. [ Medical Education ](https://mdster.com/blog?category=medical-education) 4. Malignant Pleural Effusion: Diagnosis, Prognosis, and Management [ Medical Education ](https://mdster.com/blog?category=medical-education) Malignant Pleural Effusion: Diagnosis, Prognosis, and Management ================================================================== A high-yield bedside guide to cytology, IPC versus pleurodesis, and the prognostic thinking that drives good pleural decisions [ MDster Editorial Team ](https://mdster.com/about) · Apr 12, 2026 · 7 min read · 47 [ Reviewed by Dr. Ali Ragab, MBBCH, MSc, MCAI ](https://mdster.com/medical-reviewers/dr-ali-ragab) [Editorial Policy](https://mdster.com/editorial-policy) | [Corrections Policy](https://mdster.com/corrections) [ Board Review ](https://mdster.com/blog?tag=board-review) [ Internal Medicine ](https://mdster.com/blog?tag=internal-medicine) [ Pleural Disease ](https://mdster.com/blog?tag=pleural-disease) [ Pulmonology ](https://mdster.com/blog?tag=pulmonology) [ Oncology ](https://mdster.com/blog?tag=oncology) ![Malignant Pleural Effusion: Diagnosis, Prognosis, and Management](https://mdster.com/storage/blog/images/malignant-pleural-effusion-diagnosis-prognosis-and-management.jpg) Share this article Share this post One of the easiest ways to frustrate a patient with cancer is to keep re-draining the same pleural effusion without deciding what the fluid means and what the next procedure is supposed to achieve. **Malignant pleural effusion (MPE)** is not just a chest X-ray finding; it usually marks advanced malignancy, drives disabling dyspnea, and carries a median survival measured in months rather than years. That is why the real skill is not memorizing drainage options. It is choosing the right intervention for the patient’s lung mechanics, prognosis, and goals of care. [\[1\]](#cite-1 "Reference [1]") Diagnosis: prove malignancy, but do not worship cytology -------------------------------------------------------- Start with **ultrasound-guided thoracentesis**. The 2023 BTS guideline recommends sending **25–50 mL** of pleural fluid for cytology, ideally with both direct smear and **cell block** preparation. Cytology should be the **initial diagnostic test** for suspected secondary pleural malignancy, but a negative result is not a permission slip to stop thinking; it should trigger further investigation when suspicion remains high. [\[2\]](#cite-2 "Reference [2]") The board-relevant number is that pleural fluid cytology is only **moderately sensitive overall**. A 2022 systematic review found an overall sensitivity of **58.2%**, with major variation by tumor type: high in **lung adenocarcinoma** at **83.6%**, but poor in **lung squamous cell carcinoma** at **24.2%** and **mesothelioma** at **28.9%**. That is the exam trap: a negative cytology does **not** exclude MPE, and it especially does not exclude mesothelioma. If mesothelioma, pleural thickening, or a low-yield histology is on the table, move early to tissue. [\[3\]](#cite-3 "Reference [3]") Tissue matters even more now because diagnosis is no longer just about naming the cancer; it may need to support histologic subtyping and molecular treatment planning. BTS recommends **thoracoscopic or image-guided pleural biopsy** depending on the situation and specifically advises against blind pleural biopsy. The ERS/EACTS statement likewise supports **tissue biopsy as the gold standard** for diagnosis and treatment planning. [\[2\]](#cite-2 "Reference [2]") Before you talk about definitive management, do one more practical thing: if you are unsure whether the patient’s dyspnea is actually coming from the effusion, or whether the lung will re-expand, perform a **large-volume therapeutic thoracentesis**. ATS/STS/STR recommends this step because symptom response and lung expandability are what separate a good pleurodesis candidate from a bad one. [\[4\]](#cite-4 "Reference [4]") IPC or pleurodesis: the real decision point is lung expandability ----------------------------------------------------------------- If the lung is **expandable**, both **indwelling pleural catheter (IPC)** and **chemical pleurodesis** are guideline-supported first-line options. If the lung is **nonexpandable**, pleurodesis is much less attractive and ATS/STS/STR favors **IPC**; BTS makes the same practical point, especially when non-expandable lung is radiologically significant. Also remember the board pitfall: do **not** default to repeated thoracenteses in a patient with recurrent symptomatic MPE and reasonable prognosis. BTS recommends a definitive pleural intervention over serial aspirations, particularly when the patient is likely to live long enough to benefit. [\[4\]](#cite-4 "Reference [4]") ApproachBest fitMain trade-off**Talc pleurodesis**Expandable lung, patient wants a catheter-free endpointUsually needs a chest tube or thoracoscopy and is less likely to work if the lung will not re-expand. [\[2\]](#cite-2 "Reference [2]")**IPC**Nonexpandable lung, failed pleurodesis, loculated effusion, or preference for outpatient palliationShorter hospital stay and fewer repeat pleural procedures, but ongoing drainage, body-image burden, cellulitis, blockage, and loculations matter. [\[4\]](#cite-4 "Reference [4]") The concept is simple: **pleurodesis tries to eliminate the pleural space; IPC accepts the space and manages it at home**. AMPLE showed fewer hospital days with IPC than with talc pleurodesis, and meta-analysis shows IPCs reduce repeat pleural procedures at the cost of more catheter-related minor complications such as cellulitis. Dyspnea relief is broadly similar, so the decision is usually about logistics, expandability, and patient preference rather than symptom efficacy alone. [\[5\]](#cite-5 "Reference [5]") Nuances boards love and wards forget ------------------------------------ First, do not wait for chemotherapy to rescue the pleural space. BTS specifically advises **not delaying definitive pleural intervention until after systemic anticancer therapy**. Second, if you place an IPC and the patient wants eventual catheter removal, **daily drainage** increases pleurodesis rates, but BTS also reminds us that daily drainage is **not required** just to control breathlessness. Third, in patients with expandable lung, **talc can be instilled through the IPC** when achieving pleurodesis and removing the catheter matters; the IPC-PLUS trial showed this increases the chance of pleurodesis versus IPC alone. [\[2\]](#cite-2 "Reference [2]") Prognosis: every drainage choice is also a goals-of-care choice --------------------------------------------------------------- MPE usually means advanced cancer and a poor prognosis, with median survival across malignancies commonly around **3–12 months**. That is not just background trivia; it should shape procedure choice. The **LENT** score is the best-known externally validated tool and stratifies patients into low-, moderate-, and high-risk groups with median survivals of **319**, **130**, and **44 days** in the original study. The **PROMISE** score is a prospectively validated model that estimates **3-month mortality**. BTS suggests using validated prognostic scores when the information will actually help treatment planning or patient discussions. [\[1\]](#cite-1 "Reference [1]") Use these scores as framing devices, not dictators. A younger patient with good performance status, expandable lung, and tumor biology that may respond to systemic therapy may reasonably value a pleurodesis pathway. A frail patient with high short-term mortality risk may benefit more from an outpatient-first IPC strategy that minimizes hospitalization. That last step is partly an inference, but it fits the survival data, the ambulatory advantage of IPC, and the way current guidelines prioritize individualized decision-making. [\[6\]](#cite-6 "Reference [6]") > **Clinical Pearl:** If pleural cytology is negative but CT shows pleural thickening or nodularity, or mesothelioma is plausible, stop repeating low-yield taps and get pleural tissue. That is where trainees waste the most time. [\[3\]](#cite-3 "Reference [3]") Key Takeaways ------------- - Send **25–50 mL** of pleural fluid for cytology and cell block, but remember that negative cytology does **not** exclude MPE. [\[2\]](#cite-2 "Reference [2]") - Overall cytology sensitivity is about **58%**, but it is much better in adenocarcinoma than in squamous carcinoma or mesothelioma. [\[3\]](#cite-3 "Reference [3]") - Choose between **IPC** and **pleurodesis** by asking whether the lung re-expands after drainage; **nonexpandable lung pushes you toward IPC**. [\[4\]](#cite-4 "Reference [4]") - Recurrent symptomatic MPE deserves a **definitive pleural plan**, not endless repeat thoracenteses. [\[2\]](#cite-2 "Reference [2]") - Treat MPE as both a respiratory problem and a prognostic event; **LENT** and **PROMISE** can sharpen conversations about procedure choice and goals of care. [\[6\]](#cite-6 "Reference [6]") MPE is one of those diagnoses where good Internal Medicine is visible: you relieve dyspnea, get the right tissue, and choose a procedure that matches the patient’s lung mechanics and life expectancy. Do that well, and you stop practicing reflex drainage and start practicing pleural medicine. [\[4\]](#cite-4 "Reference [4]") Frequently Asked Questions ---------------------------- When should I repeat pleural cytology after a negative result? Repeat cytology is most reasonable when the first sample was small or suboptimal. If mesothelioma, pleural thickening, or a low-yield tumor type is suspected, move early to image-guided or thoracoscopic biopsy instead. [\[2\]](#cite-2 "Reference [2]") Does a negative pleural cytology rule out malignant pleural effusion? No. Cytology is highly specific but only moderately sensitive overall, and performance is especially poor in mesothelioma and squamous lung cancer. [\[3\]](#cite-3 "Reference [3]") How do I choose between IPC and pleurodesis at the bedside? Ask whether the lung expands after drainage. Expandable lung supports either IPC or pleurodesis; nonexpandable lung, failed pleurodesis, or loculation generally favors IPC. [\[4\]](#cite-4 "Reference [4]") Does IPC relieve dyspnea less well than pleurodesis? Not usually. Symptom relief is broadly similar, but IPC generally reduces hospital time and repeat pleural procedures while adding catheter-care burdens and minor catheter-related complications. [\[5\]](#cite-5 "Reference [5]") Should definitive pleural intervention wait until systemic cancer therapy starts? No. Current BTS guidance advises against deferring definitive pleural intervention until after systemic anticancer therapy. [\[2\]](#cite-2 "Reference [2]") References (11) ------------------- 1. 1. [ pubmed.ncbi.nlm.nih.gov/39831480 ](https://pubmed.ncbi.nlm.nih.gov/39831480/) [↩](#cite-ref-1-1 "Back to text") 2. 2. [ Roberts ME, Rahman NM, Maskell NA, et al. British Thoracic Society Guideline for Pleural Disease: Summary of Guideline. Thorax. 2023. ](https://www.brit-thoracic.org.uk/document-library/guidelines/pleural-disease/bts-guideline-for-pleural-disease-summary-of-guideline/) [↩](#cite-ref-2-1 "Back to text") 3. 3. [ pubmed.ncbi.nlm.nih.gov/35110369 ](https://pubmed.ncbi.nlm.nih.gov/35110369/) [↩](#cite-ref-3-1 "Back to text") 4. 4. [ www.atsjournals.org/doi/10.1164/rccm.201807-1415ST ](https://www.atsjournals.org/doi/10.1164/rccm.201807-1415ST) [↩](#cite-ref-4-1 "Back to text") 5. 5. [ Thomas R, Fysh ETH, Smith NA, et al. Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial. JAMA. 2017. ](https://pubmed.ncbi.nlm.nih.gov/29164255/) [↩](#cite-ref-5-1 "Back to text") 6. 6. [ pmc.ncbi.nlm.nih.gov/articles/PMC4251306 ](https://pmc.ncbi.nlm.nih.gov/articles/PMC4251306/) [↩](#cite-ref-6-1 "Back to text") 7. 7. [ Balekian AA, et al. Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline. Am J Respir Crit Care Med. 2018. ](https://pubmed.ncbi.nlm.nih.gov/30272503/) 8. 8. [ Diagnostic sensitivity of pleural fluid cytology in malignant pleural effusions: systematic review and meta-analysis. Thorax. 2023. ](https://thorax.bmj.com/content/78/1/32) 9. 9. [ Clive AO, Kahan BC, Hooper CE, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014. ](https://pubmed.ncbi.nlm.nih.gov/25100651/) 10. 10. [ Psallidas I, Kanellakis NI, Gerry S, et al. Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis. Lancet Respir Med. 2018. ](https://pubmed.ncbi.nlm.nih.gov/29908990/) 11. 11. [ Bhatnagar R, Keenan EK, Morley AJ, et al. Outpatient Talc Administration by Indwelling Pleural Catheter for Malignant Effusion. N Engl J Med. 2018. ](https://pubmed.ncbi.nlm.nih.gov/29617585/) Keep going Turn reading into Internal Medicine performance ------------------------------------------------- - System‑based, exam‑style questions + explanations - Smarter review to reinforce weak topics - Build confidence with measurable progress [ Start practicing ](https://mdster.com/user/dashboard) [ Explore Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ View pricing ](https://mdster.com/pricing) [ Explore features ](https://mdster.com/features) No credit card required. Full access to all features. No commitment. Cancel anytime. Explore topics: [ # Board Review ](https://mdster.com/blog?tag=board-review) [ # Internal Medicine ](https://mdster.com/blog?tag=internal-medicine) [ # Pleural Disease ](https://mdster.com/blog?tag=pleural-disease) [ # Pulmonology ](https://mdster.com/blog?tag=pulmonology) [ # Oncology ](https://mdster.com/blog?tag=oncology) [ Back to all posts ](https://mdster.com/blog) Discussion () ----------------- Join the discussion [ Log in ](https://mdster.com/auth/login) or [ Sign up ](https://mdster.com/auth/register) No comments yet Be the first to share your thoughts! ![]() More in Medical Education ------------------------- [ See all ](https://mdster.com/blog?category=medical-education) [### Pediatric Hemangiomas and Vascular Lesions: A Practical Overview 6 min read Apr 11, 2026 ](https://mdster.com/blog/pediatric-hemangiomas-and-vascular-lesions-a-practical-overview) [### Coagulopathy-Directed Therapy in Massive Hemorrhage 4 min read Apr 10, 2026 ](https://mdster.com/blog/coagulopathy-directed-therapy-in-massive-hemorrhage) [### Compartment Syndrome and Crush Injury Disposition in the ED 6 min read Apr 09, 2026 ](https://mdster.com/blog/compartment-syndrome-and-crush-injury-disposition-in-the-ed) Related Posts ------------- [ ![Autism Spectrum Disorder vs Social Anxiety in a 9-Year-Old](https://mdster.com/storage/blog/images/autism-spectrum-disorder-vs-social-anxiety-in-a-9-year-old.jpg) Case Discussion ### Autism Spectrum Disorder vs Social Anxiety in a 9-Year-Old A board-style child psychiatry case on distinguishing autism spectrum disorder from social anxiety, interpreting meltdowns, and planning neurodiversity-affirming care. 6 min read 0 comments ](https://mdster.com/blog/autism-spectrum-disorder-vs-social-anxiety-in-a-9-year-old) [ ![Pediatric Hemangiomas and Vascular Lesions: A Practical Overview](https://mdster.com/storage/blog/images/pediatric-hemangiomas-and-vascular-lesions-a-practical-overview.jpg) Medical Education ### Pediatric Hemangiomas and Vascular Lesions: A Practical Overview A focused pediatric guide to infantile hemangiomas and vascular lesions, with high-yield clues for distinguishing malformations and knowing when propranolol should not wait. 6 min read 0 comments ](https://mdster.com/blog/pediatric-hemangiomas-and-vascular-lesions-a-practical-overview) [ ![Coagulopathy-Directed Therapy in Massive Hemorrhage](https://mdster.com/storage/blog/images/coagulopathy-directed-therapy-in-massive-hemorrhage.jpg) Medical Education ### Coagulopathy-Directed Therapy in Massive Hemorrhage A high-yield anesthesiology review of coagulopathy-directed therapy in massive hemorrhage, with a practical focus on fibrinogen, platelets, and viscoelastic testing. 4 min read 0 comments ](https://mdster.com/blog/coagulopathy-directed-therapy-in-massive-hemorrhage) [ ![Compartment Syndrome and Crush Injury Disposition in the ED](https://mdster.com/storage/blog/images/compartment-syndrome-and-crush-injury-disposition-in-the-ed.jpg) Medical Education ### Compartment Syndrome and Crush Injury Disposition in the ED Disposition is treatment in compartment syndrome and crush injury. Learn who needs the OR, monitored admission, serial electrolyte checks, or urgent transfer. 6 min read 0 comments ](https://mdster.com/blog/compartment-syndrome-and-crush-injury-disposition-in-the-ed) [ ![Royal College of Physicians and Surgeons of Canada (Internal Medicine Applied/Oral Component): Study Tips That Actually Work](https://mdster.com/storage/blog/images/royal-college-of-physicians-and-surgeons-of-canada-internal-medicine-appliedoral-component.jpg) Study Tips ### Royal College of Physicians and Surgeons of Canada (Internal Medicine Applied/Oral Component): Study Tips That Actually Work Preparing for the Royal College of Physicians and Surgeons of Canada Internal Medicine Applied/Oral Component? Use this practical plan to train mock orals, clinical judgement, and examiner-friendly answers. 6 min read 0 comments ](https://mdster.com/blog/royal-college-of-physicians-and-surgeons-of-canada-internal-medicine-appliedoral-component) [ ![Medication Considerations in PTSD: SSRIs, SNRIs, Prazosin](https://mdster.com/storage/blog/images/medication-considerations-in-ptsd-ssris-snris-prazosin.jpg) Medical Education ### Medication Considerations in PTSD: SSRIs, SNRIs, Prazosin A board-focused review of PTSD pharmacotherapy: when to choose sertraline, paroxetine, or venlafaxine, why benzodiazepines are a trap, and how to use prazosin carefully for nightmares. 7 min read 0 comments ](https://mdster.com/blog/medication-considerations-in-ptsd-ssris-snris-prazosin) [ ](/) Master your medical exams with evidence-based learning. [ GET IT ON Google Play ](https://play.google.com/store/apps/details?id=com.mdster.app) ### Platform - [Home](https://mdster.com) - [Features](https://mdster.com/features) - [Pricing](https://mdster.com/pricing) - [About](https://mdster.com/about) ### Resources - [Blog](https://mdster.com/blog) - [Dashboard](https://mdster.com/user/dashboard) ### Support - [Contact](https://mdster.com/contact) - [Legal & Policies](https://mdster.com/legal) - [Medical Reviewers](https://mdster.com/medical-reviewers) © 2026 MDster [ ](https://play.google.com/store/apps/details?id=com.mdster.app) [Terms](https://mdster.com/terms) [Privacy](https://mdster.com/privacy) [Editorial](https://mdster.com/editorial-policy) reCAPTCHA Protected by reCAPTCHA. Google [Privacy Policy](https://policies.google.com/privacy) and [Terms of Service](https://policies.google.com/terms) apply. Cookie Consent -------------- We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. [ Terms of Use ](https://mdster.com/terms) & [ Privacy Policy ](https://mdster.com/privacy) Accept